Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Arzoxifene
LY353381 · 7 trials · 7 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Arzoxifene | DRUG | 20 mg, oral, tablet, once a day for 52 weeks |
| Raloxifene | DRUG | 60 mg, oral, tablet, once a day for 52 weeks |
| Placebo | DRUG | oral, tablet, once a day for 36 months |
| LY353381 | DRUG | - |
| tamoxifen | DRUG | - |
| arzoxifene hydrochloride | DRUG | - |
Inclusion Criteria: * Must have osteoporosis * Must be between 50 and 75 years old and be able to walk * Have at least two of your back bones that can be x-rayed * Have not had a period in at least two years * Be willing to have blood tests Exclusion Criteria: * Have a bone disease other than ost...
LY353381 is an investigational small molecule being studied for the treatment of breast neoplasms, specifically in women with locally advanced or metastatic breast cancer. It is being developed by Eli Lilly and Company and has completed a Phase 3 clinical trial.
LY353381 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The drug is an investigational small molecule in the oncology therapeutic area.
LY353381 has completed a Phase 3 clinical trial. The trial, NCT00034125, was a randomized, double-blind study comparing LY353381 to tamoxifen in women with locally advanced or metastatic breast cancer. The drug remains investigational and is not approved.
LY353381 has one completed clinical trial, NCT00034125, a Phase 3 study comparing LY353381 to tamoxifen in women with locally advanced or metastatic breast cancer. The trial was conducted in the United States, Argentina, Chile, India, and Mexico, and enrolled female participants aged 18 years and older.
LY353381 is not FDA approved. It is an investigational drug that has completed a Phase 3 clinical trial for breast cancer, but approval status has not been established. The drug remains in clinical development and is not available as a marketed therapy.